In November 2023, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information for salbutamol inhalation products to address risks associated with overuse. (ema.europa.eu) This decision underscores the importance of continuous monitoring and updating of safety information to protect public health.
In August 2024, the EMA reported a shortage of salbutamol inhalation products in several EU countries due to increased demand and manufacturing issues. The shortage was expected to continue until early 2026, highlighting the need for robust supply chain management. (ema.europa.eu)
In October 2024, the EMA endorsed restrictions on the use of short-acting beta-agonists, including salbutamol, for obstetric indications due to safety concerns. This decision reflects the agency's commitment to ensuring the safe use of medications across different patient populations. (ema.europa.eu)
In December 2024, the EMA approved a new generic version of salbutamol inhalation solution, increasing competition and potentially reducing costs for patients. This approval demonstrates the agency's support for generic medications as a means to enhance accessibility.
In February 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of salbutamol as a critical medication for respiratory conditions. This inclusion emphasizes the ongoing global recognition of salbutamol's importance in healthcare.
These developments highlight the dynamic nature of the regulatory landscape for salbutamol, emphasizing the need for manufacturers and exporters to stay informed and compliant with evolving standards and requirements.
